The cryogenic medicine team of our hospital won the 25th invention patent
Release time:
2022-03-08
Recently, the Cryomedicine Center of Shandong Yinfeng Life Sciences Research Institute (the research unit of our foundation) once again obtained the invention patent for "a placental tissue matrix material and its preparation method". Up to now, the total number of patent authorizations granted by the cryogenic medicine team from the State Intellectual Property Office has reached 25.
The patent was officially submitted on November 25, 2019, and it took two years until the patent certificate was approved. The patent discloses a placenta tissue matrix material, which is a special scaffold material containing active cytokine receptors prepared from placenta tissue. It can actively attract active ingredients in the living body into the material, causing the accumulation of active cell ingredients to support cells. Attachment, infiltrative growth, proliferation and differentiation.
The repair and reconstruction of tissues and organs has always been a research hotspot in the fields of tissue engineering, biology, and medicine. With the development of technology, tissue engineering products have gradually become clinically important surgical repairs and substitutes, and have become the mainstay of current clinical surgical treatments. It is an important treatment measure for the loss of human tissue and organs and various injuries caused by accidents and other accidents. Tissue engineering materials can be said to be the basis for the research and development of this product, and are expected to become the first choice for surgical repair and replacement in clinical practice.
At present, most tissue engineering materials use natural polymer materials that can provide bioactive components as their main components, such as collagen, gelatin, hyaluronic acid, chitosan, etc. However, these traditional tissue engineering materials have insufficient biomechanical strength and are inconsistent with the body. There are deficiencies such as poor tissue integration and mismatch between degradation rate and tissue reconstruction. Therefore, the use of decellularization technology to remove cells and DNA that cause immune responses in tissues to obtain extracellular matrix (ECM) as a biomaterial stands out in tissue engineering research.
However, although some products of domestic acellular tissue matrix (ACTM) materials have entered preclinical trials, they are mostly derived from animal collagen such as pigs and cattle. They are not only expensive, have limited clinical use effects, but also have potential Risks of infection and immune rejection, and due to the diverse surgical and clinical needs, tissue engineering products of different specifications, different scales and multiple structural and activity requirements are required, which are difficult to meet with conventional extracellular matrices and scaffolds.
To this end, Yinfeng Low Temperature Center invented and provided a medical biomaterial prepared from human placenta tissue - placenta tissue matrix material. The placental tissue matrix material of the present invention does not contain immune antigens of allogeneic tissue, retains receptors for multiple active factors in the extracellular matrix of the placental tissue, and has various forms (such as particles, gels and porous scaffolds). The placenta tissue matrix material of the present invention can be implanted into tissue defects and wounds in the body, helps accumulate active cell components, supports cell migration, attachment, proliferation and differentiation, accelerates the repair of damaged tissues, and can meet the needs of different parts and shapes. clinical needs.
Yinfeng Cryogenic Medicine Center will work hard to accelerate technological innovation, promote the transformation of results, and promote the early application of the acellular matrix obtained by this invention in the fields of burns and plastic surgery, medical cosmetology, diabetic foot, etc., and become an important surgical repair for clinically treating diseases and saving lives. and alternatives, for human health.
Latest developments
The debut and discourse of the YinFeng Life Continuation Project not only served as an authoritative demonstration of its own ethical governance framework but also contributed practical wisdom toward establishing industry norms.
Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross
Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.
The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.
Public Welfare Partnership: A Special Letter from the Jinan Red Cross
On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155515
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
